➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Colorcon
Johnson and Johnson
Express Scripts
Dow

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 7,858,300

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,858,300
Title:Methods and compositions to evaluate antibody treatment response
Abstract: The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. The invention is based on a determination of the FCGR3A genotype of a subject. The invention can be used for patients with malignancies, particularly lymphoma, and is suited to select best responders and/or adjust treatment condition or protocol for low responders.
Inventor(s): Watier; Herve (Ballan-Mire, FR), Cartron; Guillaume (Savonnieres, FR), Colombat; Philippe (Larcay, FR)
Assignee: Centre Hospitalier Regional et Universitaire de Tours (Cedex Tours, FR)
Application Number:10/492,183
Patent Claims:see list of patent claims

Details for Patent 7,858,300

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Centre Hospitalier Regional et Universitaire de Tours (Cedex Tours, FR) 2021-10-19 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Centre Hospitalier Regional et Universitaire de Tours (Cedex Tours, FR) 2021-10-19 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Centre Hospitalier Regional et Universitaire de Tours (Cedex Tours, FR) 2021-10-19 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Centre Hospitalier Regional et Universitaire de Tours (Cedex Tours, FR) 2021-10-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
McKesson
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.